Clinical Trial Update: Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immunogenicity of a measles-rubella double-antigen vaccine; the study sponsored by Bio-Manguinhos/Fiocruz has been completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Rubella

Drugs mentioned

• Measles-Rubella vaccine (MR) (Measles-Rubella vaccine)

Snippet

Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Conditions: Rubella, Measles | Phase 1 | Status: COMPLETED